Top Page
Tong Ren Tang Technologies Co
(OTC:1666)
Tong Ren Tang Technologies Co (1666) vs. S&P 500 (SPY)
Tong Ren Tang Technologies Co Business Overview & Revenue Model
Tong Ren Tang Technologies Co Financial Statement Overview
| Breakdown | ||||
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 6.77B | 5.99B | 5.40B | 4.61B | 4.48B | Gross Profit |
| 2.85B | 2.59B | 2.29B | 2.07B | 2.05B | EBIT |
| 1.12B | 1.21B | 1.08B | 943.55M | 938.26M | EBITDA |
| 1.30B | 1.39B | 1.26B | 1.14B | 1.04B | Net Income Common Stockholders |
| 590.19M | 582.89M | 507.25M | 467.55M | 417.65M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 4.24B | 4.18B | 3.89B | 3.49B | 3.94B | Total Assets |
| 13.51B | 12.48B | 11.59B | 10.94B | 10.47B | Total Debt |
| 1.63B | 1.59B | 1.64B | 1.69B | 1.46B | Net Debt |
| -1.12B | -2.13B | -1.60B | -1.26B | -1.53B | Total Liabilities |
| 3.86B | 3.47B | 3.44B | 3.19B | 3.06B | Stockholders Equity |
| 6.89B | 6.48B | 5.98B | 5.73B | 5.53B |
| Cash Flow | Free Cash Flow | |||
| 450.78M | 565.85M | 877.01M | -110.09M | 841.35M | Operating Cash Flow |
| 554.17M | 723.77M | 1.03B | 435.81M | 1.05B | Investing Cash Flow |
| -1.07B | 43.01M | -197.36M | -195.44M | 456.90M | Financing Cash Flow |
| -497.76M | -499.45M | -474.67M | -164.51M | -466.11M |
Tong Ren Tang Technologies Co Technical Analysis
Tong Ren Tang Technologies Co Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | $71.57B | 15.53 | 13.20% | 5.99% | -9.60% | -27.18% | |
70 Neutral | HK$5.48B | 6.02 | 11.61% | 6.97% | -18.09% | -15.08% | |
69 Neutral | $6.07B | 10.73 | 7.39% | 4.17% | 4.70% | -13.82% | |
66 Neutral | $71.04B | 37.42 | 6.14% | 1.54% | 7.63% | -24.23% | |
65 Neutral | $60.52B | 12.24 | 6.22% | 1.97% | -2.82% | 11.93% | |
62 Neutral | €30.78B | 8.47 | 5.71% | ― | ― | ||
52 Neutral | $5.36B | 3.88 | -42.93% | 2.87% | 17.85% | 1.45% |
Tong Ren Tang Technologies Co Corporate Events
Tong Ren Tang Technologies Co. Ltd. announced its unaudited financial results for the first quarter of 2025, reporting an operating revenue of approximately RMB2,035.42 million and a net profit of RMB227.23 million. The announcement highlights the company’s financial stability and growth potential, reinforcing its strong position in the traditional Chinese medicine industry.
Tong Ren Tang Technologies Co. Ltd. announced that its subsidiary, Beijing Tong Ren Tang Chinese Medicine Company Limited, has entered into a strategic cooperation agreement with China Duty Free International Limited. This agreement aims to leverage both parties’ strengths to expand Tong Ren Tang’s overseas markets, focusing on innovative business models and exclusive product versions. The collaboration will enhance the company’s market positioning by integrating resources and exploring multi-dimensional cooperation in business, products, and culture, particularly in the Chinese health food and beverage sector.
Tong Ren Tang Technologies Co. Ltd. has announced a final cash dividend of RMB 0.18 per share for the financial year ending December 31, 2024, with a payment date set for August 11, 2025. The announcement includes details on withholding tax rates for different categories of shareholders, highlighting a 10% rate for non-resident enterprises and individuals, and a 20% rate for those investing through the Shenzhen-Hong Kong Stock Connect. This dividend declaration reflects the company’s ongoing commitment to returning value to its shareholders, potentially enhancing its market position and investor confidence.
Tong Ren Tang Technologies Co. Ltd. reported its annual results for 2024, showing a revenue increase of 7.18% to RMB7.26 billion, despite a net profit decline of 10.62% to RMB886.93 million. The company faced challenges due to rising raw material costs and declining sales in the Chinese medicine industry but responded by adjusting marketing strategies and optimizing operations to enhance market competitiveness.
Tong Ren Tang Technologies Co. Ltd. announced that its subsidiary, Beijing Tong Ren Tang Chinese Medicine Company Limited, has received the Certificate of Registration for its proprietary medicine, Jin Chai Shi Hu San, from the Chinese Medicine Council of Hong Kong. This certification allows the product to be sold in Hong Kong, aiding in the expansion of the company’s product lines and market reach. Although the registration is a positive step for market expansion, it is not expected to have a significant immediate impact on the company’s operations or financial performance. The company advises caution due to potential influences from policy changes, exchange rates, and market competition.
Tong Ren Tang Technologies Co. Ltd. has announced a board meeting scheduled for March 28, 2025, to discuss several key financial and operational matters. The agenda includes approving the audited consolidated results for the year ending December 31, 2024, considering the recommendation of a final dividend, and potentially closing the register of members, which could have implications for shareholders and market positioning.